160132-53-6 Usage
Uses
Used in Pharmaceutical Research:
Tert-butyl 3-(2-((Methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate is used as a research compound for its potential therapeutic applications in the development of new drugs. Its unique structure and functional groups make it a promising candidate for various medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 3-(2-((Methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate serves as a versatile building block. Its reactivity and functional groups allow for the synthesis of a wide range of complex organic molecules.
Used in Anti-inflammatory and Analgesic Applications:
Tert-butyl 3-(2-((Methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate is being studied for its anti-inflammatory and analgesic properties. Its potential use in the treatment of pain and inflammation could lead to the development of new medications for these conditions.
However, it is important to note that further research is needed to fully understand the biological activity and potential medicinal uses of tert-butyl 3-(2-((Methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate. Its applications in different industries may vary based on the specific requirements and regulatory guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 160132-53-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,1,3 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 160132-53:
(8*1)+(7*6)+(6*0)+(5*1)+(4*3)+(3*2)+(2*5)+(1*3)=86
86 % 10 = 6
So 160132-53-6 is a valid CAS Registry Number.
160132-53-6Relevant articles and documents
AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
-
, (2018/12/02)
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 0288; 0289, (2015/02/19)
Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
-
, (2008/06/13)
The invention relates to cyclic urea derivatives of general formula I STR1 wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.
